WO2000005263A3 - Compounds for use in the treatment of inflammation - Google Patents

Compounds for use in the treatment of inflammation Download PDF

Info

Publication number
WO2000005263A3
WO2000005263A3 PCT/GB1999/002392 GB9902392W WO0005263A3 WO 2000005263 A3 WO2000005263 A3 WO 2000005263A3 GB 9902392 W GB9902392 W GB 9902392W WO 0005263 A3 WO0005263 A3 WO 0005263A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
inhibition
manufacture
compound
inflammation
Prior art date
Application number
PCT/GB1999/002392
Other languages
French (fr)
Other versions
WO2000005263A2 (en
Inventor
Mauro Perretti
Stephen Getting
Roderick Flower
Original Assignee
William Harvey Research Limite
Mauro Perretti
Stephen Getting
Roderick Flower
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Harvey Research Limite, Mauro Perretti, Stephen Getting, Roderick Flower filed Critical William Harvey Research Limite
Priority to AU50560/99A priority Critical patent/AU5056099A/en
Publication of WO2000005263A2 publication Critical patent/WO2000005263A2/en
Publication of WO2000005263A3 publication Critical patent/WO2000005263A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/69—Beta-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Use of a compound comprising an amino acid sequence HFRW in the manufacture of a medicament for inhibition of neutrophil chemoattractant production, inhibition of polymorphonuclear cell (PMN) accumulation, or reduction/treatment of inflammatory response/disease, and/or in the manufacture of an agonist of melanocortin receptor type 3 (MC3-R); wherein the compound is not adrenocorticotrophic hormone (ACTH)1-39 or a fragment thereof which activates the production of glucocorticoids.
PCT/GB1999/002392 1998-07-24 1999-07-22 Compounds for use in the treatment of inflammation WO2000005263A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50560/99A AU5056099A (en) 1998-07-24 1999-07-22 Compounds for use in the treatment of inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9816234.0 1998-07-24
GBGB9816234.0A GB9816234D0 (en) 1998-07-24 1998-07-24 Compounds for use in the treatment of inflammation

Publications (2)

Publication Number Publication Date
WO2000005263A2 WO2000005263A2 (en) 2000-02-03
WO2000005263A3 true WO2000005263A3 (en) 2000-05-04

Family

ID=10836177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/002392 WO2000005263A2 (en) 1998-07-24 1999-07-22 Compounds for use in the treatment of inflammation

Country Status (3)

Country Link
AU (1) AU5056099A (en)
GB (1) GB9816234D0 (en)
WO (1) WO2000005263A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
CA2453515A1 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
EP1529535A1 (en) * 2003-11-06 2005-05-11 IPF PharmaCeuticals GmbH Isolation of a circulating human lipolytic peptide
ES2642214T3 (en) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugation of peptides by transglutaminase
CA2698824A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine
AU2008306255A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of neurotrophic factor for retinal cholinergic neruons (NFRCN) and chorionic gonadotropin-beta (109-145) as therapeutic agents
EP2300036B1 (en) 2008-06-09 2017-04-05 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
UY32690A (en) 2009-06-08 2011-01-31 Astrazeneca Ab SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
CA2761607C (en) 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
WO2011063367A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
AU2010321738B2 (en) 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
CN110585215B (en) * 2019-09-19 2023-06-02 中山大学 New application of hemin and its complex in medicine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146113A2 (en) * 1983-12-15 1985-06-26 Dieter Aderhold Active agent and therapeutical composition for the treatment of deincephalon failures of nervous deseases and skin diseases
FR2691465A1 (en) * 1992-05-25 1993-11-26 Pf Medicament New melanotropin peptide(s) and polysaccharide conjugates - useful as antiinflammatory, antiallergic, immunosuppressant and skin-tanning agents
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146113A2 (en) * 1983-12-15 1985-06-26 Dieter Aderhold Active agent and therapeutical composition for the treatment of deincephalon failures of nervous deseases and skin diseases
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
FR2691465A1 (en) * 1992-05-25 1993-11-26 Pf Medicament New melanotropin peptide(s) and polysaccharide conjugates - useful as antiinflammatory, antiallergic, immunosuppressant and skin-tanning agents
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HILTZ M E ET AL: "ALPHA-MSH PEPTIDES INHIBIT ACUTE INFLAMMATION AND CONTACT SENSITIVITY", PEPTIDES,US,ELMSFORD, vol. 11, no. 5, 1 January 1990 (1990-01-01), pages 979 - 982, XP000644695, ISSN: 0196-9781 *
JAYAWICKREME E A: "Discovery and structure-function analysis of alpha-MSH antagonists", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 269, no. 47, 25 November 1994 (1994-11-25), pages 29846 - 29854-29854, XP002112308, ISSN: 0021-9258 *
PENG E A: "Binding and biological activity of C-terminally modified melanocortin peptides", PEPTIDES,US,ELMSFORD, vol. 18, no. 7, 1997, pages 1001 - 1008-1008, XP002113015, ISSN: 0196-9781 *
SCHIÖTH E A: "Selectivity of cyclic [D-Nal-7] and [D-Phe-7] substituted MSH analogues for the melanocortin receptor substypes", PEPTIDES,US,ELMSFORD, vol. 18, no. 7, 1997, pages 1009 - 1013-1013, XP002113070, ISSN: 0196-9781 *

Also Published As

Publication number Publication date
AU5056099A (en) 2000-02-14
GB9816234D0 (en) 1998-09-23
WO2000005263A2 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
WO2000005263A3 (en) Compounds for use in the treatment of inflammation
AU5090099A (en) Salts and bases of the 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
BR9910864A (en) Anti-inflammatory compounds for inhibiting cell adhesion
CA2321728A1 (en) Epiallopregnanolone in the treatment of cns disorders
EP1017382A4 (en) Biarylalkanoic acids as cell adhesion inhibitors
WO1996027664A3 (en) Antisense transcript expressed in b lymphocytes and synthetic oligonucleotides useful to inhibit the activity thereof
MY120235A (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
CA2186511A1 (en) Pyrimidinyl derivatives as interleukin inhibitors
EP1034164A4 (en) Substituted beta-alanine derivatives as cell adhesion inhibitors
CA2262692A1 (en) Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
CA2419517A1 (en) Wide slit nozzle and coating method by wide slit nozzle
CY2009010I2 (en) METHOD FOR ENRICHMENT OF R-EPIMER OF 16,17-ACETAL DERIVATIVES OF 21-ACYLOXY PREGNA-1,4-DIEN-11.BETA., 16.ALPHA., 17.ALPHA.-TRIOL-3,20-DIONE
BR9907788A (en) Paraglycocorticoid selective anti-inflammatory agents
WO2003020215A3 (en) Methods of treating mycocardial event related coditions with thymosin beta 4
CA2362281A1 (en) Combinations for the treatment of diseases involving angiogenesis
AU5147298A (en) Twin screw extruder for batch freezing
EP0751954A4 (en) Anti-inflammatory composition and method with des-tyr dynorphin and analogues
WO1998043936A3 (en) Improved methods of manufacturing betulinic acid
CA2239964A1 (en) Steroid nitrite ester derivatives useful as anti-inflammatory drugs
CA2113916A1 (en) 6-Chloro-5-Fluoro-3-(2-Thenoyl)-2-Oxindole-1-Carboxamide as an Analgesic and Anti-Inflammatory Agent
AU7671198A (en) Methods for the inhibition of neuronal activity by local delivery of adenosi ne
WO1994000555A3 (en) Compositions for the inhibition of protein hormone formation and uses thereof
AU5800896A (en) Non-steroidal anti-inflammatory drugs for the cyto-protection of the trabecular meshwork
AU6204899A (en) Novel imidazoles with anti-inflammatory activity
AU2046792A (en) Topical anti-fungal agents having anti-inflammatory activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase